-
Uncategorized2 hours agoSTAT+: Abridge inks deals with Nvidia and Lilly
NEW YORK — Health care artificial intelligence company Abridge on Thursday announced new deals with two trillion-dollar companies, pharma giant Eli Lilly and chipmaker Nvidia, as...
-
Uncategorized3 hours agoSummit pulls $500M share sale a day after announcing it
The developer of a leading PD-1/VEGF cancer drug cited “market conditions” for the cancellation. Its shares have struggled to break out following data milestones. Read More
-
Uncategorized4 hours agoFighting Antimicrobial Resistance with Biomaterials and Phages
Antimicrobial resistance (AMR) is a significant global health threat, with its impact felt across all regions of the world.1 According to the World Health Organization (WHO),...
-
Uncategorized4 hours agoSensorion, citing Regeneron competition, shifts focus to a different hearing loss therapy
A strategic review determined that the development environment had "notably changed," leading Sensorion to end work on its gene therapy for OTOF-related hearing loss. Read More
-
Uncategorized5 hours ago
Genentech R&D layoffs hit top exec who’s been with the biotech nearly 30 years
The staffing changes will focus resources on work that creates the highest impact for patients, according to Genentech. The number of employees affected is unknown, but...
-
Uncategorized5 hours agoSTAT+: Novartis doubles down on molecular glue strategy
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Medicare drug spending is climbing...
-
Uncategorized5 hours ago
Sky-high Parabilis, Kailera IPOs spur optimism—but only for derisked biotechs
Biotechs are benefitting from the AI tech frenzy and inflation, but validated pipelines and careful planning are still key to the recent record-setting IPOs, experts say.
